section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: palpitations, QT interval prolongation, tachycardia.

EENT: blurred vision.

GI: constipation, dry mouth, abdominal pain, dyspepsia, nausea.

GU: urinary tract infection.

MS: muscle weakness.

Neuro: confusion, drowsiness, hallucinations, headache.
Misc: (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)HYPERSENSITIVITY REACTIONS .

Interactions

Drug-Drug:

Availability

(Generic available)

Route/Dosage

Overactive Bladder

Renal Impairment

Hepatic Impairment

Neurogenic Detrusor Overactivity

Renal Impairment

Hepatic Impairment

US Brand Names

VESIcare, VESIcare LS

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: urinary tract antispasmodics

Pharmacologic Classification: anticholinergics

Pharmacokinetics

Absorption: 90% absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Protein Binding: 98%.

Metabolism/Excretion: Extensively metabolized by liver via the CYP3A4 isoenzyme. 69% excreted in urine as metabolites, 22% in feces.

Half-life: Tablets: 45–68 hr; Suspension: 26 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
Oralunknown3–8 hr24 hr

Patient/Family Teaching

Pronunciation

so-li-FEN-a-sin